Mr. Shakeel Mckenzie

Shakeel Mckenzie is a clinical researcher focused on infectious diseases and vaccine evaluation in South Africa. His work is closely associated with major multicenter trials assessing the safety and effectiveness of the ChAdOx1 nCoV-19 vaccine against emerging SARS-CoV-2 variants. Through collaborations published in leading medical journals, he has contributed to evidence guiding vaccine policy in variant-prevalent settings.

His research centers on COVID-19 vaccine performance, variant-specific immune responses, and real-world protection in diverse populations. Notable contributions include analyses of vaccine efficacy against the Beta and Delta variants, durability of immune protection, and safety outcomes in randomized controlled trials. These studies have informed understanding of variant-driven immune escape and public health strategy.

Mckenzie has also examined clinical and pathological features of COVID-19–related deaths and longitudinal infection patterns among healthcare workers. This work highlights expertise in cohort studies, histopathology, and epidemiological surveillance, particularly within high HIV and tuberculosis prevalence contexts, strengthening regional and global insight into pandemic response.